- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04944368
Phase II Clinical Trial of CinnaGen COVID-19 Vaccine (SpikoGen)
A Phase II, Randomized, Two-armed, Double-blind, Placebo-controlled Trial to Evaluate the Safety, Tolerability, and Immunogenicity of an Adjuvanted Recombinant SARS-CoV-2 Spike (S) Protein Subunit Vaccine Candidate (SpikoGen)
This is a phase II, randomized, two-armed, double-blind, placebo-controlled trial designed to evaluate the safety, tolerability, and immunogenicity of a candidate adjuvanted recombinant SARS-CoV-2 spike (S) protein subunit vaccine (SpikoGen) produced by CinnaGen Co. 400 adult individuals receive either SARS-CoV-2 recombinant spike protein (25 µg) with Advax-SM adjuvant (15 mg) or saline placebo in a 3:1 ratio. The injection is given in two doses with a 21-day interval in the deltoid muscle of the non-dominant arm. The randomization was stratified by age (<65 or ≥65) and health conditions of potential risk for severe COVID-19. Participants will be visited at two weeks and will be followed up for six months after the second dose of the study intervention.
Study hypotheses include:
- The adjuvanted COVID-19 vaccine candidate is safe and tolerable in adult subjects.
- The adjuvanted COVID-19 vaccine candidate induces strong immunogenicity against SARS-CoV-2 in adult subjects.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Tehran, Iran, Islamic Republic of, 1981846911
- Espinas Palace Hotel
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female ≥18 years
- Willing and able to comply with all study requirements, including scheduled visits, interventions, and laboratory tests
- Healthy adults or adults in a stable medical condition, defined as not being hospitalized within 3 months prior to the screening visit
- Females must not be pregnant or breastfeeding
Exclusion Criteria:
- Subjects with signs of active SARS-COV-2 infection at the screening visit.
- Subjects with body temperature of 38 degrees Celsius or greater at the screening visit or within 72 hours prior to the screening visit.
- Subjects with a history of any progressive or severe neurological disorders, seizure, or Guillain-Barre syndrome.
- Subjects who receive immunosuppressive or cytotoxic medications.
- Female Subjects who are pregnant or breastfeeding or have planned to become pregnant during the study period.
- Subjects who have a history of severe allergic reactions (e.g., anaphylaxis) to the study vaccine, any components of the study interventions, or any pharmaceutical products.
- Subjects who have received any other investigational products within 30 days prior to the screening visit or intend to participate in any other clinical studies during the period of this study.
- Subjects who have been vaccinated with any vaccine or vaccine candidate against SARS-CoV-2.
- Subjects who have received any vaccines within 28 days prior to the screening visit or intend to receive any vaccines up to 14 days after the second dose of the study injection.
- Subjects who have any known bleeding disorders or, in the investigator's opinion, have any contraindications for an intramuscular injection.
- Subjects who have received any blood, plasma, or immunoglobulin products from 90 days prior to the screening visit or intend to receive during the study period.
- Subjects with any condition that may increase the risk of participating in the study or may interfere with the evaluation of the primary endpoints of the study in the investigator's opinion.
- Subjects who have donated ≥450 mL of blood or blood products within 28 days prior to the screening visit.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Saline placebo
|
0.9% sodium chloride (1 mL) injection in two doses with a 21-day interval administered with intramuscular injections in the non-dominant arm
Other Names:
|
Experimental: Vaccine candidate
|
SARS-CoV-2 recombinant spike protein (25 µg) with Advax-SM adjuvant (15 mg) in two doses with a 21-day interval administered with intramuscular injections in the non-dominant arm
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of solicited adverse events
Time Frame: For 7 days after each dose
|
Injection site pain, erythema, swelling, and induration, axillary swelling or tenderness ipsilateral to the side of injection, fever (oral temperature), headache, fatigue, myalgia, arthralgia, nausea, vomiting, and chills, as reported by the study participants on electronic diaries, and as defined using system organ classes and preferred terms of the Medical Dictionary for Regulatory Activities (MedDRA)
|
For 7 days after each dose
|
Incidence of unsolicited adverse events
Time Frame: For 28 days after each dose
|
As reported by the study participants on electronic diaries, and as defined using system organ classes and preferred terms of the Medical Dictionary for Regulatory Activities (MedDRA)
|
For 28 days after each dose
|
Percentage of participants with seroconversion for S1 binding IgG antibodies after the first injection
Time Frame: 21 days after the first dose (on the day of the second dose)
|
As measured by ELISA
|
21 days after the first dose (on the day of the second dose)
|
Percentage of participants with seroconversion for S1 binding IgG antibodies after the second injection
Time Frame: 14 days after the second dose
|
As measured by ELISA
|
14 days after the second dose
|
Change in geometric mean concentration (GMC) for S1 binding IgG antibodies from baseline to 21 days after the first injection
Time Frame: On the day of the first dose and 21 days after the first dose (on the day of the second dose)
|
As measured by ELISA
|
On the day of the first dose and 21 days after the first dose (on the day of the second dose)
|
Change in geometric mean concentration (GMC) for S1 binding IgG antibodies from baseline to 14 days after the second injection
Time Frame: On the day of the first dose and 14 days after the second dose
|
As measured by ELISA
|
On the day of the first dose and 14 days after the second dose
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of serious adverse events (SAEs) and suspected unexpected serious adverse reaction (SUSARs)
Time Frame: For 6 months after the second dose
|
As defined using system organ classes and preferred terms of the Medical Dictionary for Regulatory Activities (MedDRA)
|
For 6 months after the second dose
|
Percentage of participants with seroconversion for SARS-CoV-2 neutralizing antibodies after the first injection
Time Frame: 21 days after the first dose (on the day of the second dose)
|
As measured by ELISA (sVNT)
|
21 days after the first dose (on the day of the second dose)
|
Percentage of participants with seroconversion for SARS-CoV-2 neutralizing antibodies after the first injection
Time Frame: 21 days after the first dose (on the day of the second dose)
|
As measured by cVNT
|
21 days after the first dose (on the day of the second dose)
|
Percentage of participants with seroconversion for SARS-CoV-2 neutralizing antibodies after the second injection
Time Frame: 14 days after the second dose
|
As measured by ELISA (sVNT)
|
14 days after the second dose
|
Percentage of participants with seroconversion for SARS-CoV-2 neutralizing antibodies after the second injection
Time Frame: 14 days after the second dose
|
As measured by cVNT
|
14 days after the second dose
|
Percentage of participants with seroconversion for receptor-binding domain (RBD) binding IgA antibodies after the first injection
Time Frame: 21 days after the first dose (on the day of the second dose)
|
As measured by ELISA
|
21 days after the first dose (on the day of the second dose)
|
Percentage of participants with seroconversion for receptor-binding domain (RBD) binding IgA antibodies after the second injection
Time Frame: 14 days after the second dose
|
As measured by ELISA
|
14 days after the second dose
|
Percentage of participants with seroconversion for S1 binding IgA antibodies after the first injection
Time Frame: 21 days after the first dose (on the day of the second dose)
|
As measured by ELISA
|
21 days after the first dose (on the day of the second dose)
|
Percentage of participants with seroconversion for S1 binding IgA antibodies after the second injection
Time Frame: 14 days after the second dose
|
As measured by ELISA
|
14 days after the second dose
|
Percentage of participants with seroconversion for receptor-binding domain (RBD) binding IgG antibodies after the first injection
Time Frame: 21 days after the first dose (on the day of the second dose)
|
As measured by ELISA
|
21 days after the first dose (on the day of the second dose)
|
Percentage of participants with seroconversion for receptor-binding domain (RBD) binding IgG antibodies after the second injection
Time Frame: 14 days after the second dose
|
As measured by ELISA
|
14 days after the second dose
|
Change in geometric mean concentration (GMC) for receptor-binding domain (RBD) binding IgG antibodies from baseline to 21 days after the first injection
Time Frame: On the day of the first dose and 21 days after the first dose (on the day of the second dose)
|
As measured by ELISA
|
On the day of the first dose and 21 days after the first dose (on the day of the second dose)
|
Change in geometric mean concentration (GMC) for receptor-binding domain (RBD) binding IgG antibodies from baseline to 14 days after the second injection
Time Frame: On the day of the first dose and 14 days after the second dose
|
As measured by ELISA
|
On the day of the first dose and 14 days after the second dose
|
Geometric mean fold rise (GMFR) for S1 binding IgG antibodies after the first injection
Time Frame: 21 days after the first dose (on the day of the second dose)
|
As measured by ELISA
|
21 days after the first dose (on the day of the second dose)
|
Geometric mean fold rise (GMFR) for S1 binding IgG antibodies after the second injection
Time Frame: 14 days after the second dose
|
As measured by ELISA
|
14 days after the second dose
|
Geometric mean fold rise (GMFR) for receptor-binding domain (RBD) binding IgG antibodies after the first injection
Time Frame: 21 days after the first dose (on the day of the second dose)
|
As measured by ELISA
|
21 days after the first dose (on the day of the second dose)
|
Geometric mean fold rise (GMFR) for receptor-binding domain (RBD) binding IgG antibodies after the second injection
Time Frame: 14 days after the second dose
|
As measured by ELISA
|
14 days after the second dose
|
Geometric mean fold rise (GMFR) for SARS-CoV-2 neutralizing antibodies after the first injection
Time Frame: 21 days after the first dose (on the day of the second dose)
|
As measured by ELISA (sVNT)
|
21 days after the first dose (on the day of the second dose)
|
Geometric mean fold rise (GMFR) for SARS-CoV-2 neutralizing antibodies after the second injection
Time Frame: 14 days after the second dose
|
As measured by ELISA (sVNT)
|
14 days after the second dose
|
Change in geometric mean concentration (GMC) for SARS-CoV-2 neutralizing antibodies from baseline to 21 days after the first injection
Time Frame: On the day of the first dose and 21 days after the first dose (on the day of the second dose)
|
As measured by ELISA (sVNT)
|
On the day of the first dose and 21 days after the first dose (on the day of the second dose)
|
Change in geometric mean concentration (GMC) for SARS-CoV-2 neutralizing antibodies from baseline to 14 days after the second injection
Time Frame: On the day of the first dose and 14 days after the second dose
|
As measured by ELISA (sVNT)
|
On the day of the first dose and 14 days after the second dose
|
Change in geometric mean concentration (GMC) for S1 binding IgA antibodies from baseline to 21 days after the first injection
Time Frame: On the day of the first dose and 21 days after the first dose (on the day of the second dose)
|
As measured by ELISA
|
On the day of the first dose and 21 days after the first dose (on the day of the second dose)
|
Change in geometric mean concentration (GMC) for S1 binding IgA antibodies from baseline to 14 days after the second injection
Time Frame: On the day of the first dose and 14 days after the second dose
|
As measured by ELISA
|
On the day of the first dose and 14 days after the second dose
|
Geometric mean fold rise (GMFR) for S1 binding IgA antibodies after the first injection
Time Frame: 21 days after the first dose (on the day of the second dose)
|
As measured by ELISA
|
21 days after the first dose (on the day of the second dose)
|
Geometric mean fold rise (GMFR) for S1 binding IgA antibodies after the second injection
Time Frame: 14 days after the second dose
|
As measured by ELISA
|
14 days after the second dose
|
Change in T-cell proliferation responses from baseline to 21 days after the first injection
Time Frame: On the day of the first dose and 21 days after the first dose (on the day of the second dose)
|
Evaluation of CD4+ and CD8+ T-cell proliferation responses as measured by flow cytometry
|
On the day of the first dose and 21 days after the first dose (on the day of the second dose)
|
Change in T-cell proliferation responses from baseline to 14 days after the second injection
Time Frame: On the day of the first dose and 14 days after the second dose
|
Evaluation of CD4+ and CD8+ T-cell proliferation responses as measured by flow cytometry
|
On the day of the first dose and 14 days after the second dose
|
Change in T-cell IFN-γ secretion from baseline to 21 days after the first injection
Time Frame: On the day of the first dose and 21 days after the first dose (on the day of the second dose)
|
As measured by IGRA
|
On the day of the first dose and 21 days after the first dose (on the day of the second dose)
|
Change in T-cell IFN-γ secretion from baseline to 14 days after the second injection
Time Frame: On the day of the first dose and 14 days after the second dose
|
As measured by IGRA
|
On the day of the first dose and 14 days after the second dose
|
Collaborators and Investigators
Sponsor
Collaborators
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Coronavirus Infections
- Coronaviridae Infections
- Nidovirales Infections
- RNA Virus Infections
- Virus Diseases
- Infections
- Respiratory Tract Infections
- Respiratory Tract Diseases
- Pneumonia, Viral
- Pneumonia
- Lung Diseases
- COVID-19
- Physiological Effects of Drugs
- Immunologic Factors
- Myeloma Proteins
- Paraproteins
Other Study ID Numbers
- VAC.CIN.PT.II
- IRCT20150303021315N23 (Registry Identifier: Iranian Registry of Clinical Trials)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Covid19
-
Anavasi DiagnosticsNot yet recruiting
-
Ain Shams UniversityRecruiting
-
Israel Institute for Biological Research (IIBR)Completed
-
Colgate PalmoliveCompleted
-
Christian von BuchwaldCompleted
-
Luye Pharma Group Ltd.Shandong Boan Biotechnology Co., LtdActive, not recruiting
-
University of ZurichLabor Speiz; Swiss Armed Forces; Universitätsspital ZürichEnrolling by invitation
-
Alexandria UniversityCompleted
Clinical Trials on SARS-CoV-2 recombinant spike protein + Advax-SM adjuvant
-
CinnagenVaxine Pty LtdCompleted
-
CinnagenShahid Beheshti University of Medical Sciences; Vaxine Pty LtdCompletedCOVID-19Iran, Islamic Republic of
-
CinnagenVaxine Pty LtdCompletedCOVID-19Iran, Islamic Republic of
-
CinnagenVaxine Pty LtdCompleted
-
Sanofi Pasteur, a Sanofi CompanyGlaxoSmithKlineActive, not recruitingCOVID-19Honduras, United States, Australia, France, Kenya, Mexico, New Zealand, Panama, Spain, United Kingdom
-
Institute for Clinical and Experimental MedicineCompletedKidney TransplantationCzechia
-
Sanofi Pasteur, a Sanofi CompanyActive, not recruitingCOVID-19United States, Colombia, Ghana, Honduras, India, Japan, Kenya, Mexico, Nepal, Nigeria, Sri Lanka, Uganda, Ukraine
-
PT Bio FarmaNot yet recruiting
-
PT Bio FarmaUniversitas PadjadjaranActive, not recruiting
-
Livzon Pharmaceutical Group Inc.Active, not recruiting